I'm not a math guy.
I became a journalist in no small part because all the other degrees at my college required scary-sounding courses such as multivariable calculus or linear algebra or Fourier Analysis and Partial Differential Equations. The school of communications was willing to award me a degree for successfully completing Math for Mutants.
I'm also not really a finance guy. The Fool hired me to be the managing editor of its newsletters to ensure that the finance guys got their stories across in a way you'd want to read.
As for my investing history, I loaded up on Ballard
In the Fool-wide stock-picking game, I went with Fannie Mae
To be honest, I'm not even sure what kind of investor I am. On Monday, I'm solidly behind the idea of investing in companies that pay dividends. By Tuesday afternoon, I'm a convert to the small-cap crusade and am searching for the next Middleby
I tell people that my scattered approach is an intentional effort at diversified asset allocation, but that's pretty much a crock. It's investing schizophrenia.
Let growth stocks grow your portfolio
The smart people here assure me there's nothing taboo about this lack of stylistic focus, and it's not like I'd be able to pick a single approach, even if they told me I had to. Not every investor meshes perfectly with an investing approach. No biggie.
But for some, the match is obvious. My daughter, Leah, is much more single-minded in her approach to stock picking -- she's a Rule Breakers girl, through and through. The oversimplified idea behind Rule Breakers is to examine companies that might not be a Big Deal yet , but could very well be someday. The newsletter service -- led by Fool co-founder David Gardner, the always-enthusiastic borderline zealot who sits two desks back over my left shoulder -- tries to identify companies with competent management, sound balance sheets, and above all, great ideas. Not just great ideas, but revolutionary ideas that have the potential to fundamentally alter the way business is done today. These picks don't always make sense to the masses, but five years ago eBay's
Of course, not all of the picks are going to prove David's visionary qualities that quickly -- and yes, I think it's safe to call someone a visionary if they invested in Dell, AOL, Starbucks
Waiting for her chip to come in
Leah is already pretty interested in the potential of nanotechnology, and as a 20-month-old, she can afford to wait for the day when the advances scientists are making in the labs of nanotechnology companies move from the theoretical to the real and reach the market. But with nanotech companies popping up almost daily with bold promises to revolutionize the future, Leah's not sure which ones are worthy of her investment allowance.
For her and her like-minded investors, Rule Breakers devotes two analysts to the nanotech world for subscribers. They're examining what all the nano players -- public and private -- are working on, and how far along they are in the process. When one of these companies figures out how to make computers spring to life instantly or create an elevator that allows us to inexpensively and safely ferry people to and from the upper reaches of space, we'll be able to capitalize on the riches that are certain to accompany these advances.
Leah is also bullish on biotechnology, but her preschool isn't yet teaching the unit on RNA and DNA. And even in her top-notch school district, it's doubtful she'd be able to make much sense of these companies, which are in most cases simply a blend of science and optimism. The Rule Breakers biotech analyst has a master's degree in pharmacology and physiology, so he actually understands the science that's going on in all those beakers and test tubes, and he can make sense of it from an investing perspective. He put my daughter onto Vertex Pharmaceuticals
Vertex already has a couple of drugs on the market that are doing well, and the company's shares are up about 28% since it was recommended in February (and Leah bought a couple of weeks later, so she got most of that bump). But more importantly, the company has an abundance of drugs in the pipeline, which could mean a much bigger pile of money down the road. Just think about it: If Leah is an investor now in a company that is somehow able to figure out the puzzle of cancer and develop a cure, the rewards would be nearly incomprehensible. I understand it's possibly irresponsibly optimistic of me to even think that way, but remember that Leah has a decade or two to wait for this to come to fruition. The cures for many diseases are out there, waiting to be discovered, and Vertex seems well-positioned to bring them to the public.
Big returns require big ideas
The risk is that Vertex won't be the big winner -- it could bomb -- and that's a real risk with any Rule Breaker. Leah agonized over for that for days; she didn't want to become a burden on her retired parents down the road because of a few failed investments. But my colleague John Reeves made a great point in a recent commentary that really grabbed Leah's attention. He took us back to the summer of 1992 and gave us a $100,000 inheritance and had us invest equally in four companies, including Starbucks. Even if the other three companies went under in the first year of operation, John opined, that initial $100,000 investment would now be worth just north of $1 million. We're looking at a 916% overall return with a .250 batting average.
Granted, Starbucks is a pretty nice example, but it's exactly the type of disruptive, market-changing company that David and his team are scouting and recommending over at Rule Breakers. Full disclosure: This is the sales pitch portion of the program. But I only suggest you take a free, no-obligation 30-day trial because it makes sense. I believe in Rule Breakers and all the other Motley Fool publications -- I wouldn't work here if I didn't -- and I believe a subscription will make you a better investor. I completely believe it will make you money. Click here to learn more.
Leah's already doing well on her Rule Breakers investments -- she's itching to buy a new tricycle, but I'm committed to teaching her the logic of a buy-and-hold approach -- but the best is still down the road. And you don't have to be a math or finance genius to figure that one out.
Roger Friedman is the managing editor of newsletters and the author of Nipple Confusion, Uncoordinated Pooping and Spittle: The Life of a Newborn's Father . He (and his daughter) own shares of Ballard and Vertex Pharmaceuticals. Middleby is a Motley Fool Hidden Gems recommendation. Fannie Mae is a Motley Fool Inside Value recommendation. The Motley Fool isinvestors writing for investors.